Dividend compounder review

ALNY

Alnylam Pharmaceuticals Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score49.00/100
Confidence82.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 14.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 23.0 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.5 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 8.5 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$313.7M
Free Cash Flow$465.4M
FCF Covers DividendUnknown
Debt / Equity2.76
P/E70.9
Revenue Growth 5Y49.8%
Net Margin12.6%
ROE90.4%
Price vs Trend-17.6%
3Y Return46.8%
5Y Return61.3%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Debt to equity is elevated at 2.76.
Dividend diary

Activity record

ALNY dividend review warning Warning · Warning

Debt to equity is elevated at 2.76.